Form 4: Amgen EVP & CFO Peter Griffith Reports Stock and Option Awards
SEC Form 4 Filing
Peter Griffith, EVP & CFO of Amgen, reports the acquisition of restricted stock units and non-qualified stock options.
Summary
- Peter Griffith, the EVP & CFO of Amgen, filed a Form 4 detailing changes in beneficial ownership.
- On May 7, 2024, Griffith acquired 3,196 shares of common stock in the form of Restricted Stock Units (RSUs).
- These RSUs vest in three annual installments starting May 7, 2026.
- Griffith also acquired 20,767 non-qualified stock options with an exercise price of $300.30.
- These options also vest in three annual installments starting May 7, 2026.
- Following these transactions, Griffith beneficially owns 35,973 shares of Amgen common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reports routine executive compensation. It's a standard practice and doesn't indicate any specific positive or negative outlook for the company.
Positives
- The grant of RSUs and stock options to a key executive like the CFO can be seen as an incentive to align their interests with the company's long-term performance.
Future Outlook
The document does not contain specific forward-looking statements about the company's overall performance, but the vesting schedules of the RSUs and stock options suggest a multi-year horizon for executive incentives.
Industry Context
Executive compensation in the biotechnology industry often includes stock options and restricted stock units to incentivize long-term growth and align executive interests with shareholder value. This filing reflects a standard practice in the industry.
Comparison to Industry Standards
- Amgen's executive compensation practices, including the use of RSUs and stock options, are generally in line with industry standards for large-cap biotechnology companies.
- Companies like Gilead Sciences, Biogen, and Regeneron also utilize similar equity-based compensation plans to incentivize their executives.
- The vesting schedules and exercise prices are typical for such grants, designed to reward sustained performance over several years.
Stakeholder Impact
- Shareholders may view the equity grants as a positive sign, aligning management's interests with long-term company performance.
- Employees may see the grants as a reflection of the company's commitment to incentivizing its leadership.
Key Dates
| Date | Description |
|---|---|
| 05/07/2024 | Date of transaction: Grant of RSUs and stock options. |
| 05/07/2026 | First vesting date for both RSUs and stock options (33%). |
| 05/07/2027 | Second vesting date for both RSUs and stock options (33%). |
| 05/07/2028 | Final vesting date for both RSUs and stock options (34%). |
| 05/08/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.